Scandinavian ChemoTech signs a new service agreement in India and receives a new order for the IQwave™ Treatment Kits

Scandinavian ChemoTech has today signed a service agreement with Catalyst Biomedicals in Pune in India. By signing this agreement ChemoTech receives an order for €3.600.

The purpose of this service agreement is to give Catalyst Biomedicals an opportunity to promote ChemoTech’s IQwave™ and Tumour Specific Electroporation in Pune and surroundings cities. The order is for treatment kits that Catalyst Biomedicals shall use to increase the market presence in the region of Pune.

Catalyst Biomedicals is a distributor with 5 years of experience in the field of marketing and distribution of medical devices and pharma. They represent companies like, Smith & Nephew, Incisive Surgical, Cefaly & Nuvigen, VSY Ophthalmic Pvt Ltd, Dentsply Sirona Pvt Ltd, Wondrx, Cardinal Health among others and has more than 20 private hospitals and hospital groups in their client list.

“It feels good that the number of partners for distribution is increasing in India, we hope this will generate more reference clinicals that can help us establish more clinical data and revenues “, says Mohan Frick CEO.

For further information please contact:

Mohan Frick, Co-Founder and CEO

+46 (0)10-218 93 00



Scandinavian ChemoTech AB (publ)

ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, tumour specific electroporation, available for treatment of both for humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where tumour specific electroporation can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Västra Hamnen Corporate Finance AB is the company's Certified Adviser. Read more at: